Merck's Keytruda to gain 3rd approval for endometrial cancerFebruary 03, 2023 - Merck's (MSD) Keytruda is already approved in two endometrial cancer indications in the U.S.
Keytruda is an example of a platform molecule, similar to ONCY's pelareorep, that is capable of being used in multiple cancers and then in multiple indications in each cancer type.
https://www.biospace.com/article/merck-eyes-third-endometrial-cancer-nod-for-keytruda-/